A meta-analysis by Mantovani et al. [36] recently evaluated the current state of randomized clinical trials for GLP-1 RA for the treatment of NAFLD/NASH, focusing on six placebo-controlled and five active-controlled studies. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.